Pemvidutide (ALT-801): The Muscle-Preserving GLP-1/Glucagon Dual Agonist — Complete 2026 Guide

In the rapidly evolving world of GLP-1 medications, a new contender is generating significant scientific interest — not just for how much weight it helps people lose, but for what kind of weight. Pemvidutide, developed by Altimmune under the research name ALT-801, is a once-weekly injectable dual agonist of the GLP-1 and glucagon receptors. Its standout property: it appears to preserve lean muscle mass at rates roughly twice as good as semaglutide (Ozempic/Wegovy) and substantially better than tirzepatide (Mounjaro/Zepbound).

This guide covers everything currently known about pemvidutide — its mechanism, clinical trial data, comparison to existing GLP-1 drugs, its emerging role in fatty liver disease and alcohol use disorder, and what to expect from the pipeline in 2026 and beyond.

What Is Pemvidutide?

Pemvidutide (INN; also known as ALT-801) is an investigational, once-weekly subcutaneous peptide drug developed by Altimmune, Inc. It is a balanced dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). Unlike pure GLP-1 receptor agonists like semaglutide, pemvidutide simultaneously activates both receptor pathways, producing a distinct metabolic profile that may address one of the biggest criticisms of current GLP-1 medications: muscle and lean tissue loss.

As of 2026, pemvidutide is not yet FDA-approved but holds:

• FDA Breakthrough Therapy Designation for metabolic dysfunction-associated steatohepatitis (MASH) — granted January 2026
• FDA Fast Track Designation for alcohol use disorder (AUD)
• Positive Phase 2 data across obesity, MASH, and AUD indications

How Pemvidutide Works: Dual GLP-1/Glucagon Mechanism

To understand pemvidutide's advantages, it helps to understand what each receptor does:

GLP-1 Receptor Agonism

Activating GLP-1 receptors drives the well-established effects of drugs like semaglutide: appetite suppression, delayed gastric emptying, improved insulin secretion, and reduced food intake. This is the primary driver of weight loss in current incretin therapies.

Glucagon Receptor Agonism

Glucagon activation is where pemvidutide differentiates itself. Glucagon receptor activation:

• Increases energy expenditure — glucagon boosts basal metabolic rate, essentially telling the body to burn more calories at rest
• Drives hepatic fat oxidation — glucagon directly stimulates fatty acid oxidation in the liver and inhibits lipogenesis, reducing liver fat independent of weight loss
• Promotes lipolysis — preferentially mobilizes fat stores for energy rather than lean tissue

The concept is that GLP-1 acts as a "diet" component (caloric restriction signal) while glucagon acts as an "exercise" component (energy expenditure signal). By combining both, pemvidutide theoretically mimics the metabolic effects of diet and exercise simultaneously — something no single GLP-1 drug achieves on its own.

The MOMENTUM Trial: Weight Loss Results

The Phase 2 MOMENTUM trial (NCT04881760) enrolled 391 adults with obesity (BMI ≥30, or ≥27 with a weight-related comorbidity) and ran for 48 weeks. Participants received weekly subcutaneous injections of pemvidutide at 1.2 mg, 1.8 mg, or 2.4 mg, or placebo.

Key Weight Loss Findings:

• Pemvidutide 2.4 mg: 15.6% mean body weight reduction vs. 2.2% placebo
• Pemvidutide 1.8 mg: ~11% mean body weight reduction
• Pemvidutide 1.2 mg: ~10% mean body weight reduction

While 15.6% weight loss at the highest dose trails semaglutide 2.4 mg (which achieves ~15–17% in STEP trials) and tirzepatide 15 mg (which achieves ~20–22%), the MOMENTUM results are considered solidly competitive — especially when body composition is factored in.

The trial also showed meaningful improvements in blood pressure, triglycerides, LDL cholesterol, and fasting glucose — the metabolic markers most relevant to cardiovascular and metabolic health outcomes.

The Lean Mass Preservation Advantage: The Number That Changes Everything

This is where pemvidutide's data becomes genuinely striking. In an MRI-based body composition sub-study of 50 participants from the MOMENTUM trial, researchers measured exactly what type of tissue was lost:

Of total weight lost, only 21.9% was lean soft tissue. The remaining 78.1% was fat mass.

To understand why this matters, compare it to existing drugs:

Losing 40% of your weight loss as muscle is a significant concern. Muscle mass affects metabolism, physical function, bone density, and long-term health outcomes. Physicians and patients increasingly identify lean mass preservation as a critical factor — particularly for older adults, athletes, and those undergoing significant weight loss.

Altimmune presented these data at the American Diabetes Association's 84th Scientific Sessions, where pemvidutide was described as having "class-leading" lean mass preservation. The mechanism behind this advantage is the glucagon receptor activation, which promotes fat-preferential energy mobilization and lipolysis while having a relatively neutral-to-sparing effect on muscle protein catabolism.

Pemvidutide for MASH (Metabolic-Associated Steatohepatitis)

Beyond obesity, pemvidutide has emerged as a potentially powerful treatment for MASH (formerly called NASH) — a progressive liver disease characterized by fat accumulation, inflammation, and fibrosis that currently has limited treatment options.

IMPACT Phase 2b Trial

The IMPACT trial evaluated pemvidutide specifically in patients with MASH across two doses (1.2 mg and 1.8 mg weekly) versus placebo. Results were published in The Lancet and presented as a late-breaking oral presentation at AASLD The Liver Meeting 2025.

48-week IMPACT results (announced December 2025):

• Statistically significant improvements in Enhanced Liver Fibrosis (ELF) score vs. placebo
• Statistically significant reductions in Liver Stiffness Measurement (LSM) — a non-invasive marker of fibrosis
• Continued antifibrotic activity from Week 24 to Week 48, showing progressive improvement over time
• Favorable tolerability profile with low treatment-related discontinuation rates

Why does pemvidutide work for MASH specifically? The glucagon receptor component is key. Glucagon receptor activation directly reduces liver fat through hepatic fatty acid oxidation and inhibition of lipogenesis — mechanisms that work independently of weight loss. This makes pemvidutide particularly attractive for MASH patients who may not need to lose large amounts of weight but need targeted liver fat reduction.

Phase 3 Program

Following the IMPACT success and the FDA Breakthrough Therapy Designation granted in January 2026, Altimmune plans to initiate a Phase 3 registrational trial for pemvidutide in MASH in 2026. Breakthrough Therapy Designation means the FDA will provide intensive guidance and may expedite review — a significant regulatory milestone.

Pemvidutide for Alcohol Use Disorder

Perhaps the most unexpected application of pemvidutide is alcohol use disorder (AUD), a condition affecting over 28 million Americans annually with very limited pharmacological options.

GLP-1 receptors are expressed in reward pathways in the brain, and early data on GLP-1 agonists suggest they may reduce cravings for alcohol. Pemvidutide received FDA Fast Track Designation for AUD, and two trials are underway:

• RECLAIM (Phase 2): ~100 patients with AUD randomized 1:1 to pemvidutide 2.4 mg or placebo for 24 weeks. Primary endpoint: reduction in heavy drinking days per week. Enrollment was completed ahead of schedule in November 2025, with topline results expected in 2026.
• RESTORE (Phase 2): Evaluating pemvidutide in alcohol-associated liver disease (ALD) — the severe end of alcohol-related liver injury. Initiated July 2025.

The dual GLP-1/glucagon mechanism may be particularly relevant for AUD: GLP-1R signaling attenuates reward-seeking behavior, while the liver-protective glucagon effects could directly address the hepatic damage caused by heavy alcohol use.

Dosing and Administration

Pemvidutide is administered once weekly via subcutaneous injection, similar to semaglutide and tirzepatide. In clinical trials, the following doses have been studied:

• 1.2 mg/week — used primarily in MASH trials
• 1.8 mg/week — used across obesity and MASH trials
• 2.4 mg/week — highest obesity dose; required a 4-week titration period

The drug is not currently available outside of clinical trials. No commercial formulation or approved dosing regimen exists as of April 2026.

Side Effects and Safety Profile

Pemvidutide's safety profile in Phase 2 trials is broadly similar to other GLP-1 medications, though generally well-tolerated:

Common Adverse Events

• Nausea: Most frequent adverse event (~33% of treated patients), predominantly mild-to-moderate and transient
• Vomiting and diarrhea: Mild-to-moderate GI events that generally resolved without treatment
• Constipation: Mild cases reported

Safety Highlights

• No major adverse cardiac events (MACE) observed in Phase 2 trials
• No significant arrhythmia signal — important given the glucagon component, as isolated glucagon can increase heart rate
• Low discontinuation rates — 0% in the 1.2 mg group, ~1% in the 1.8 mg group in MASH studies
• Favorable blood pressure and lipid effects — consistent reductions in both systolic BP and triglycerides

One theoretical concern with any glucagon receptor agonist is hyperglycemia (since glucagon raises blood glucose). However, in pemvidutide trials, the GLP-1 component appears to offset this, with no clinically significant glucose elevation observed. The balance between GLP-1 and glucagon activity appears well-calibrated in the pemvidutide molecule.

Pemvidutide vs. Semaglutide vs. Tirzepatide: How Does It Compare?

The key takeaway: pemvidutide doesn't necessarily beat semaglutide or tirzepatide on absolute weight loss numbers, but its lean mass preservation profile is arguably the best data we have from any approved or investigational GLP-1-class drug. For patients where muscle preservation is a priority — older adults, people with sarcopenic obesity, athletes, or anyone concerned about the "Ozempic body" phenomenon — pemvidutide represents a potentially meaningful clinical advance.

2026 Pipeline: What's Next for Pemvidutide?

As of April 2026, Altimmune's pipeline priorities for pemvidutide are:

1. MASH Phase 3 initiation: Following FDA Breakthrough Therapy Designation, Altimmune has aligned with the FDA on Phase 3 registrational trial parameters. Phase 3 initiation is planned for 2026. If trials succeed, a MASH NDA filing could come in 2028–2029.
2. RECLAIM AUD results: Topline data from the 24-week alcohol use disorder trial are expected in 2026, with the possibility of Fast Track review accelerating a pathway to approval if results are positive.
3. Obesity positioning: While pemvidutide has not announced a Phase 3 obesity trial, its lean mass data continue to attract attention from the scientific community and potential partners. A combination with a myostatin inhibitor or other muscle-protective agent is a speculated future direction.

Conclusion: A Different Kind of GLP-1 Drug

Pemvidutide represents a genuinely distinct approach in a crowded GLP-1 landscape. While semaglutide and tirzepatide dominate the market by sheer weight-loss numbers, pemvidutide makes the case that quality of weight loss matters as much as quantity. Losing primarily fat while preserving muscle isn't just aesthetically preferable — it has real implications for metabolic health, physical function, and long-term outcomes.

Its emerging role in MASH treatment — where the glucagon mechanism provides liver-specific benefits beyond weight reduction — and its exploratory use in alcohol use disorder point toward a drug that may ultimately find its niche not in head-to-head obesity competition with tirzepatide, but in specialized metabolic medicine: the patient with fatty liver disease, the person concerned about muscle loss, the individual with concurrent alcohol-related liver injury.

Phase 3 trials and 2026 data readouts will be critical milestones. Pemvidutide is not yet a drug you can prescribe or access — but among the next generation of metabolic medicines, it is one of the most scientifically interesting candidates to watch.

This article is for educational purposes only. Pemvidutide is investigational and not FDA-approved. Consult a qualified healthcare provider before making any medical decisions.